Developer docs
API playgroundTry for free, no card

Search company profiles

Intellia Therapeutics

Full company profile

uuid0000e29

Namestring
Intellia Therapeutics
Legal namestring
Intellia Therapeutics, Inc.
Websiteurl
intelliatx.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Intellia Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts, that develops CRISPR/Cas9-based gene editing therapies using both in vivo (lipid nanoparticle delivery to liver cells) and ex vivo (engineered cell therapy) approaches. Its lead candidates are lonvo-z (NTLA-2002) for hereditary angioedema, which targets the KLKB1 gene to durably reduce plasma kallikrein activity, and nex-z (NTLA-2001) for transthyretin amyloidosis, which targets the TTR gene; both are one-time treatments delivered via lipid nanoparticles. The technology platform is built on a Nobel Prize-winning foundation (co-founder Jennifer Doudna shared the 2020 Chemistry Nobel) and the company is the first to achieve a positive Phase 3 readout for an in vivo CRISPR gene editor, with a rolling BLA submission initiated in April 2026 and a planned H1 2027 US commercial launch for lonvo-z.

The company currently generates revenue almost entirely through collaboration and milestone payments — primarily from a 2016 partnership with Regeneron covering ATTR and hemophilia programs (under which Regeneron shares 25% of worldwide development costs and commercial profits for ATTR and holds a US co-promotion option) — rather than from product sales. FY2025 revenue was $67.7 million (+17% YoY) against a $412.7 million net loss, reflecting heavy investment in clinical development and pre-commercial buildout. The commercial organization is being constructed around a specialty pharmacy and hospital distribution model targeting rare disease specialists, led by SVP Commercial Maria Natale (former Takeda TAKHZYRO US launch lead), with approximately 32 commercial hires including 29 sales positions and 3 market access/HEOR roles. The company ended early 2026 with approximately $605 million in cash, extended by an April 2026 underwritten public offering of approximately $180 million at $10.75 per share, and carries a market capitalization of approximately $1.55-1.95 billion.

Additional pipeline programs include an allogeneic CD19 CAR-T cell therapy for B-cell-mediated autoimmune diseases partnered with Kyverna Therapeutics, the wholly owned AvenCell oncology CAR-T programs (AVC-201 and AVC-203), and a hemophilia B program co-developed with Regeneron. The company is publicly traded on NASDAQ under ticker NTLA and employs 251-500 people.

Short descriptiontext

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing one-time CRISPR/Cas9 in vivo gene editing therapies delivered via lipid nanoparticles, with lonvo-z for hereditary angioedema in rolling BLA review and nex-z for ATTR amyloidosis in Phase 3, targeting a H1 2027 commercial launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene editing, in vivo therapeutics, lipid nanoparticle delivery, rare disease treatments, genome editing platform
Industry3 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Collaboration and Milestone Payments
TypeLicensing Royalties
Description

Intellia's primary revenue model relies on collaboration payments and milestone income from pharmaceutical partners rather than commercial product revenue. The company receives development milestones and potential future royalties from Regeneron (ATTR program, hemophilia), AvenCell, and Kyverna partnerships.

ad-hoc-news.de
2Future Product Sales
TypeOne Time License
Description

Upon FDA approval and commercial launch, expected to generate revenue from product sales. Lonvo-z (if approved for HAE) and nex-z (if approved for ATTR amyloidosis) would be one-time treatments with potential premium pricing. FY2025 revenue was $67.7 million, up 17% year-over-year, driven by collaboration income from Regeneron.

defenseworld.net
3Grant and Research Funding
TypeSubscription Recurring
Description

The company has historically received grant funding and research support. FY2025 revenue of $67.7 million with 17% YoY growth, though still operating at a net loss of $412.7 million.

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1One-time gene editing therapy - pricing model not yet established
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Gene editing therapies are typically priced as one-time treatments with potential for premium pricing. Analyst projections estimate peak annual sales of $500 million to $3.5 billion depending on indication and market penetration. The company noted expected gross margins exceeding 95% for commercial products.

biopharmadive.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing one-time CRISPR/Cas9-based gene editing therapies through in vivo (LNP delivery to liver hepatocytes) and ex vivo (engineered cell therapy) approaches. Its lead candidates are lonvo-z for hereditary angioedema (HAE) and nex-z for transthyretin (ATTR) amyloidosis, with partnered programs in hemophilia (Regeneron) and allogeneic CAR-T cell therapy (AvenCell, Kyverna).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 87% reduction in mean monthly HAE attacks vs placebo (Phase 3 HAELO trial)
+6 more records
Product overview1 text field

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing CRISPR/Cas9-based gene editing therapies through both in vivo (direct delivery) and ex vivo (engineered cell therapy) approaches. The company's lead product candidates include lonvo-z (lonvoguran ziclumeran) for hereditary angioedema and nex-z (nexiguran ziclumeran) for ATTR amyloidosis, both delivered via lipid nanoparticles targeting liver cells. Additional pipeline programs include hemophilia treatments partnered with Regeneron and allogeneic CAR-T cell therapies for oncology through AvenCell.

Product and service3 records
1Lonvo-z (lonvoguran ziclumeran, NTLA-2002)
CategoryCore product candidate (in vivo gene editing therapy)
Description

A one-time in vivo CRISPR/Cas9-based gene editing therapy for hereditary angioedema (HAE) that targets the KLKB1 gene in hepatocytes to durably reduce plasma kallikrein activity and prevent excess bradykinin production, intended for HAE specialists and patients with recurrent life-threatening swelling attacks. Currently under rolling BLA submission to the FDA.

2Nex-z (nexiguran ziclumeran, NTLA-2001)
CategoryCore product candidate (in vivo gene editing therapy)
Description

A one-time in vivo CRISPR/Cas9-based gene editing therapy for transthyretin (ATTR) amyloidosis targeting the TTR gene in hepatocytes. In Phase 3 development for both ATTR amyloidosis with polyneuropathy (ATTRv-PN, MAGNITUDE-2) and ATTR amyloidosis with cardiomyopathy (ATTR-CM, MAGNITUDE). Partnered with Regeneron Pharmaceuticals.

3REGV131-LNP1265 (Hemophilia B)
CategoryPartnered research-stage program
Description

A CRISPR/Cas9-based treatment for hemophilia B using targeted transgene insertion capabilities, being co-developed with Regeneron Pharmaceuticals. Regeneron is advancing the hemophilia B (and hemophilia A research-stage) programs with Intellia eligible for development milestones and royalties.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

License and collaboration agreement to research, develop and potentially commercialize CRISPR/Cas9-based therapeutic products focused on genome editing in the liver. Regeneron shares 25% of worldwide development costs and commercial profits for the ATTR program and has an option to enter into a co-promotion agreement for U.S. commercialization of ATTR therapies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AvenCell was launched by Intellia, Blackstone Life Sciences, Cellex Cell Professionals GmbH and GEMoaB (now AvenCell Europe GmbH) to develop next-generation universal CAR-T immunotherapies for difficult-to-treat cancers using Intellia's allogeneic cell engineering platform. AVC-201 and AVC-203 are wholly owned by AvenCell.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing and collaboration agreement for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various B-cell-mediated autoimmune diseases. Intellia provides its differentiated allogeneic cell engineering platform.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Broader RNAi therapeutics incumbent with approved drugs targeting HAE (e.g., in this disease area family) and ATTR amyloidosis (AMVUTTRA). Represents the principal therapeutic alternative to Intellia's one-time gene editing approach, with an established commercial footprint in both lead indications.

TypeBroad incumbent
Description

Broader mRNA and LNP technology incumbent with extensive lipid nanoparticle delivery platform expertise. Comparable through LNP delivery technology overlap (the delivery vehicle for Intellia's in vivo CRISPR programs), though focused on vaccines and protein-encoding therapeutics rather than gene editing.

TypeBroad incumbent
Description

Broad biotech incumbent with significant gene therapy exposure via the CASGEVY collaboration with CRISPR Therapeutics. Comparable as an established commercial-stage biotech operating in the curative medicine space Intellia targets, with deep rare-disease commercial expertise.

TypeEmerging player
Description

Emerging prime editing company pursuing in vivo and ex vivo gene editing therapies. Comparable as a next-generation gene editing platform peer, though earlier-stage than Intellia with no Phase 3 programs.

TypeDirect peer
Description

Direct peer developing CRISPR-based gene editing medicines, including Casgevy (now Verve/Vertex) and in vivo ophthalmology programs. Comparable as a clinical-stage CRISPR company using similar technology foundation, with overlapping competitive positioning in rare diseases.

TypeDirect peer
Description

Clinical-stage gene editing and gene therapy peer using zinc finger nucleases (ZFN) and AAV delivery. Comparable as a platform-based genomic medicine developer with overlapping target diseases and similar business model, though using an earlier-generation editing modality.

TypeDirect peer
Description

Direct CRISPR/Cas9 gene editing peer and pioneer; co-developed CASGEVY (exa-cel) with Vertex for sickle cell disease and beta-thalassemia — the first commercial CRISPR therapy. Comparable in core technology (CRISPR/Cas9) and platform-based approach, though historically focused on ex vivo applications.

TypeDirect peer
Description

Direct peer in next-generation gene editing, developing base editing and prime editing therapies. Comparable as a clinical-stage gene editing platform targeting rare and serious diseases, with similar business model and therapeutic area overlap.

TypeBroad incumbent
Description

Strategic partner and broader biopharmaceutical incumbent with substantial gene therapy pipeline. Comparable through the active co-development arrangement covering Intellia's ATTR program (nex-z), with overlap in rare disease commercialization capability.

TypeDirect peer
Description

In vivo gene editing peer using LNP delivery to edit genes in the liver for cardiovascular disease. Directly comparable in delivery modality (LNP-CRISPR) and target organ (liver), representing a clear competitor in the in vivo editing space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intellia Therapeutics

Gene Therapy Pharmaceuticalsintelliatx.com

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing one-time CRISPR/Cas9 in vivo gene editing therapies delivered via lipid nanoparticles, with lonvo-z for hereditary angioedema in rolling BLA review and nex-z for ATTR amyloidosis in Phase 3, targeting a H1 2027 commercial launch.

What Intellia Therapeutics does

Intellia Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts, that develops CRISPR/Cas9-based gene editing therapies using both in vivo (lipid nanoparticle delivery to liver cells) and ex vivo (engineered cell therapy) approaches. Its lead candidates are lonvo-z (NTLA-2002) for hereditary angioedema, which targets the KLKB1 gene to durably reduce plasma kallikrein activity, and nex-z (NTLA-2001) for transthyretin amyloidosis, which targets the TTR gene; both are one-time treatments delivered via lipid nanoparticles. The technology platform is built on a Nobel Prize-winning foundation (co-founder Jennifer Doudna shared the 2020 Chemistry Nobel) and the company is the first to achieve a positive Phase 3 readout for an in vivo CRISPR gene editor, with a rolling BLA submission initiated in April 2026 and a planned H1 2027 US commercial launch for lonvo-z.

The company currently generates revenue almost entirely through collaboration and milestone payments — primarily from a 2016 partnership with Regeneron covering ATTR and hemophilia programs (under which Regeneron shares 25% of worldwide development costs and commercial profits for ATTR and holds a US co-promotion option) — rather than from product sales. FY2025 revenue was $67.7 million (+17% YoY) against a $412.7 million net loss, reflecting heavy investment in clinical development and pre-commercial buildout. The commercial organization is being constructed around a specialty pharmacy and hospital distribution model targeting rare disease specialists, led by SVP Commercial Maria Natale (former Takeda TAKHZYRO US launch lead), with approximately 32 commercial hires including 29 sales positions and 3 market access/HEOR roles. The company ended early 2026 with approximately $605 million in cash, extended by an April 2026 underwritten public offering of approximately $180 million at $10.75 per share, and carries a market capitalization of approximately $1.55-1.95 billion.

Additional pipeline programs include an allogeneic CD19 CAR-T cell therapy for B-cell-mediated autoimmune diseases partnered with Kyverna Therapeutics, the wholly owned AvenCell oncology CAR-T programs (AVC-201 and AVC-203), and a hemophilia B program co-developed with Regeneron. The company is publicly traded on NASDAQ under ticker NTLA and employs 251-500 people.

Intellia Therapeutics firmographics

Firmographics
Name
Intellia Therapeutics
Legal name
Intellia Therapeutics, Inc.
Website
https://intelliatx.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Intellia Therapeutics is a clinical-stage biopharmaceutical company developing one-time CRISPR/Cas9 in vivo gene editing therapies delivered via lipid nanoparticles, with lonvo-z for hereditary angioedema in rolling BLA review and nex-z for ATTR amyloidosis in Phase 3, targeting a H1 2027 commercial launch.
Ownership category
akta.pro rank

Intellia Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • CRISPR gene editing
  • In vivo therapeutics
  • Lipid nanoparticle delivery
  • Rare disease treatments
  • Genome editing platform

Where Intellia Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Intellia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Collaboration and Milestone Payments: Intellia's primary revenue model relies on collaboration payments and milestone income from pharmaceutical partners rather than commercial product revenue. The company receives development milestones and potential future royalties from Regeneron (ATTR program, hemophilia), AvenCell, and Kyverna partnerships.
  2. Future Product Sales: Upon FDA approval and commercial launch, expected to generate revenue from product sales. Lonvo-z (if approved for HAE) and nex-z (if approved for ATTR amyloidosis) would be one-time treatments with potential premium pricing. FY2025 revenue was $67.7 million, up 17% year-over-year, driven by collaboration income from Regeneron.
  3. Grant and Research Funding: The company has historically received grant funding and research support. FY2025 revenue of $67.7 million with 17% YoY growth, though still operating at a net loss of $412.7 million.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goOne-time gene editing therapy - pricing model not yet established

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Intellia Therapeutics product offering

Product offering

Core offering

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing one-time CRISPR/Cas9-based gene editing therapies through in vivo (LNP delivery to liver hepatocytes) and ex vivo (engineered cell therapy) approaches. Its lead candidates are lonvo-z for hereditary angioedema (HAE) and nex-z for transthyretin (ATTR) amyloidosis, with partnered programs in hemophilia (Regeneron) and allogeneic CAR-T cell therapy (AvenCell, Kyverna).

Product overview

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing CRISPR/Cas9-based gene editing therapies through both in vivo (direct delivery) and ex vivo (engineered cell therapy) approaches. The company's lead product candidates include lonvo-z (lonvoguran ziclumeran) for hereditary angioedema and nex-z (nexiguran ziclumeran) for ATTR amyloidosis, both delivered via lipid nanoparticles targeting liver cells. Additional pipeline programs include hemophilia treatments partnered with Regeneron and allogeneic CAR-T cell therapies for oncology through AvenCell.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lonvo-z (lonvoguran ziclumeran, NTLA-2002) A one-time in vivo CRISPR/Cas9-based gene editing therapy for hereditary angioedema (HAE) that targets the KLKB1 gene in hepatocytes to durably reduce plasma kallikrein activity and prevent excess bradykinin production, intended for HAE specialists and patients with recurrent life-threatening swelling attacks. Currently under rolling BLA submission to the FDA.
  • Nex-z (nexiguran ziclumeran, NTLA-2001) A one-time in vivo CRISPR/Cas9-based gene editing therapy for transthyretin (ATTR) amyloidosis targeting the TTR gene in hepatocytes. In Phase 3 development for both ATTR amyloidosis with polyneuropathy (ATTRv-PN, MAGNITUDE-2) and ATTR amyloidosis with cardiomyopathy (ATTR-CM, MAGNITUDE). Partnered with Regeneron Pharmaceuticals.
  • REGV131-LNP1265 (Hemophilia B) A CRISPR/Cas9-based treatment for hemophilia B using targeted transgene insertion capabilities, being co-developed with Regeneron Pharmaceuticals. Regeneron is advancing the hemophilia B (and hemophilia A research-stage) programs with Intellia eligible for development milestones and royalties.

Quantifiable outcome

  • 87% reduction in mean monthly HAE attacks vs placebo (Phase 3 HAELO trial)
  • +6 more outcomes

Companies that use Intellia Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Intellia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Intellia Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Regeneron PharmaceuticalscoreStrategic or Co-development PartnerLicense and collaboration agreement to research, develop and potentially commercialize CRISPR/Cas9-based therapeutic products focused on genome editing in the liver. Regeneron shares 25% of worldwide development costs and commercial profits for the ATTR program and has an option to enter into a co-promotion agreement for U.S. commercialization of ATTR therapies.
  • AvenCellcoreStrategic or Co-development PartnerAvenCell was launched by Intellia, Blackstone Life Sciences, Cellex Cell Professionals GmbH and GEMoaB (now AvenCell Europe GmbH) to develop next-generation universal CAR-T immunotherapies for difficult-to-treat cancers using Intellia's allogeneic cell engineering platform. AVC-201 and AVC-203 are wholly owned by AvenCell.
  • Kyverna TherapeuticscoreStrategic or Co-development PartnerLicensing and collaboration agreement for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various B-cell-mediated autoimmune diseases. Intellia provides its differentiated allogeneic cell engineering platform.

Scale indicators9 records

Recent moves5 records

Expansion highlights6 records

Intellia Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Alnylam Pharmaceuticals: Broader RNAi therapeutics incumbent with approved drugs targeting HAE (e.g., in this disease area family) and ATTR amyloidosis (AMVUTTRA). Represents the principal therapeutic alternative to Intellia's one-time gene editing approach, with an established commercial footprint in both lead indications.
  • Moderna: Broader mRNA and LNP technology incumbent with extensive lipid nanoparticle delivery platform expertise. Comparable through LNP delivery technology overlap (the delivery vehicle for Intellia's in vivo CRISPR programs), though focused on vaccines and protein-encoding therapeutics rather than gene editing.
  • Vertex Pharmaceuticals: Broad biotech incumbent with significant gene therapy exposure via the CASGEVY collaboration with CRISPR Therapeutics. Comparable as an established commercial-stage biotech operating in the curative medicine space Intellia targets, with deep rare-disease commercial expertise.
  • Regeneron Pharmaceuticals: Strategic partner and broader biopharmaceutical incumbent with substantial gene therapy pipeline. Comparable through the active co-development arrangement covering Intellia's ATTR program (nex-z), with overlap in rare disease commercialization capability.

Emerging players

  • Prime Medicine: Emerging prime editing company pursuing in vivo and ex vivo gene editing therapies. Comparable as a next-generation gene editing platform peer, though earlier-stage than Intellia with no Phase 3 programs.

Direct peers

  • Editas Medicine: Direct peer developing CRISPR-based gene editing medicines, including Casgevy (now Verve/Vertex) and in vivo ophthalmology programs. Comparable as a clinical-stage CRISPR company using similar technology foundation, with overlapping competitive positioning in rare diseases.
  • Sangamo Therapeutics: Clinical-stage gene editing and gene therapy peer using zinc finger nucleases (ZFN) and AAV delivery. Comparable as a platform-based genomic medicine developer with overlapping target diseases and similar business model, though using an earlier-generation editing modality.
  • CRISPR Therapeutics: Direct CRISPR/Cas9 gene editing peer and pioneer; co-developed CASGEVY (exa-cel) with Vertex for sickle cell disease and beta-thalassemia — the first commercial CRISPR therapy. Comparable in core technology (CRISPR/Cas9) and platform-based approach, though historically focused on ex vivo applications.
  • Beam Therapeutics: Direct peer in next-generation gene editing, developing base editing and prime editing therapies. Comparable as a clinical-stage gene editing platform targeting rare and serious diseases, with similar business model and therapeutic area overlap.
  • Verve Therapeutics: In vivo gene editing peer using LNP delivery to edit genes in the liver for cardiovascular disease. Directly comparable in delivery modality (LNP-CRISPR) and target organ (liver), representing a clear competitor in the in vivo editing space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Intellia Therapeutics social profiles

Digital presence

Intellia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intellia Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Intellia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intellia Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intellia Therapeutics

What does Intellia Therapeutics do?

Intellia Therapeutics is a clinical-stage biopharmaceutical company developing one-time CRISPR/Cas9-based gene editing therapies through in vivo (LNP delivery to liver hepatocytes) and ex vivo (engineered cell therapy) approaches. Its lead candidates are lonvo-z for hereditary angioedema (HAE) and nex-z for transthyretin (ATTR) amyloidosis, with partnered programs in hemophilia (Regeneron) and allogeneic CAR-T cell therapy (AvenCell, Kyverna).

Is Intellia Therapeutics a public or private company?

Intellia Therapeutics is a public company. It is classified as public and is currently operating.

When was Intellia Therapeutics founded?

Intellia Therapeutics was founded in 2014. It employs 501 to 1,000 people.

Where is Intellia Therapeutics based?

Intellia Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Intellia Therapeutics make money?

Three revenue lines are on record. Collaboration and Milestone Payments are the primary driver. The others are future Product Sales and grant and Research Funding.

Who are Intellia Therapeutics's main competitors?

Broad incumbents on record are Alnylam Pharmaceuticals, Moderna, Vertex Pharmaceuticals and Regeneron Pharmaceuticals. Prime Medicine is listed as an emerging player. Direct peers are Editas Medicine, Sangamo Therapeutics, CRISPR Therapeutics, Beam Therapeutics and Verve Therapeutics.

Does Intellia Therapeutics have an API?

No public API is recorded for Intellia Therapeutics.

What industry is Intellia Therapeutics in?

Intellia Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StIntellia Therapeutics (NTLA) Faces A Fresh Valuation Test After Phase 3 Enrollment WrapsIntellia Therapeutics completed enrollment in its Phase 3 trial of CRISPR therapy nex-z for hereditary transthyretin amyloidosis with polyneuropathy. The stock fell 14.29% over the past week and 21.38% over three months, trading at $9.78, while analysts see a fair value of $23.11.Investing.comIntellia at Jefferies global healthcare conference: launch and pipeline in focusIntellia Therapeutics presented at Jefferies' global healthcare conference, saying its lead CRISPR therapy lonvo-z for hereditary angioedema is under priority FDA review with a PDUFA date of 10 March 2027. The company reported $615 million in cash and said payer coverage, not physician interest, is the main rate-limiting step for launch.Investing.comIntellia stock price target maintained at $30 by Citizens on HAE dataCitizens reiterated a Market Outperform rating and $30 price target on Intellia Therapeutics after ACAAI data showed 100% of patients free from long-term prophylaxis and two-thirds attack-free. The firm's sum-of-the-parts analysis assigns $20 per share to the HAE opportunity, while the stock trades at $10.55. Intellia is set to report earnings on November 6.Seeking AlphaIntellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE TranscriptIntellia Therapeutics held an investor event on November 12, 2026, to discuss Lonvo-z, its gene-editing candidate for hereditary angioedema. The company presented seven data points at the 2026 American College of Allergy, Asthma and Immunology Scientific Meeting in Phoenix, Arizona.NatureNovel CRISPR therapy is poised to gain first FDA approval to alter genes inside the bodyIntellia Therapeutics reported that its CRISPR-Cas9 therapy lonvo-z remains effective four years after treatment for hereditary angioedema. The company has applied for FDA approval, expected by 10 March, which would make it the first in vivo CRISPR medicine. The therapy targets the prekallikrein gene to prevent swelling attacks.Stock TitanIntellia Therapeutics to present at Jefferies conferenceIntellia Therapeutics will present at the Jefferies Global Healthcare Conference in London on November 17, 2026, at 8:30 a.m. GMT. A live webcast will be available on the company's website, with a replay for approximately 90 days.YahooIntellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesIntellia Therapeutics reported a Q3 loss of $0.91 per share, missing the consensus estimate of $0.82, and revenue of $7.16 million, down 28.36% from the prior quarter. The company has surpassed consensus EPS estimates twice in four quarters but missed revenue estimates once.Quiver QuantitativeINTELLIA THERAPEUTICS ($NTLA) Releases Q3 2026 Earnings | NTLA Stock NewsINTELLIA THERAPEUTICS reported Q3 2026 earnings of -$0.91 per share, missing estimates by $0.10, and revenue of $7.16 million, missing estimates by $3.51 million. Insiders made seven sales in the past six months, while 182 institutional investors added shares and 119 reduced positions. Analysts have set a median price target of $25.0.TradingViewIntellia Therapeutics Reports Q3 2026 Results, $615M Cash and $127.5M Net LossIntellia Therapeutics reported Q3 2026 collaboration revenue of $7.2 million and a net loss of $127.5 million, with cash of $614.8 million. The FDA accepted the biologics license application for lonvo-z for hereditary angioedema with a PDUFA target of March 10, 2027. The company expects its cash to fund operations into 2028.Quiver QuantitativeIntellia Therapeutics Stock Short Interest Falls to 39.95% | NTLA Stock NewsIntellia Therapeutics short interest fell to 39.95% of the float on October 15th, totaling 44,435,219 shares, a 1.5% decrease from September 30th. Analysts have set a median price target of $25.0 for the stock.